RESEARCH ARTICLE

[View Article Online](#)
[View Journal](#) | [View Issue](#)

Cite this: *Med. Chem. Commun.*,
2017, 8, 1655

Design, synthesis, and biological evaluation of new thiazolo[5,4-*d*]pyrimidine derivatives as potent antiproliferative agents†

Zhong-Hua Li, Xue-Qi Liu, Peng-Fei Geng, Jin-Lian Ma, Tao-Qian Zhao,
Hao-Ming Wei, Bin Yu * and Hong-Min Liu*

A series of thiazolo[5,4-*d*]pyrimidine derivatives were synthesized and evaluated for their antiproliferative activities against several human cancer cell lines. Structure–activity relationship studies were carried out, showing that most of the target compounds had good inhibition against the tested cell lines. Among them, compound **7i** exhibited potent inhibition against human gastric cancer cells MGC-803 and HGC-27 with IC₅₀ values of 4.64 and 5.07 μM, respectively and around 12-fold selectivity between MGC-803 and GES-1, indicating a relatively low toxicity to normal cells. The potency and low toxicity of compound **7i** make the thiazolo[5,4-*d*]pyrimidine an attractive scaffold for designing new derivatives selectively targeting MGC-803 cells.

Received 5th April 2017,
Accepted 21st June 2017

DOI: 10.1039/c7md00165g

rsc.li/medchemcomm

Scaffold diversity has been highly pursued in the construction of small-molecule libraries, highlighting the importance of molecular scaffolds in the identification of new drugs. Of particular interest are the heterocyclic scaffolds,^{1–4} which are prevalent in drugs and natural products. Modifications in the biologically privileged scaffolds have been recognized as an important strategy to search new bioactive compounds for the treatment of diseases. Compounds bearing the bicyclic thiazolo[5,4-*d*]pyrimidine scaffold have been proved to exhibit diverse biological activities such as anti-tumor,^{5–9} antimicrobial,¹⁰ anti-inflammatory,¹¹ antinociceptive¹² and human cytomegalovirus inhibitory.¹³ For example, compound **A** as a TRPV1 (vanilloid receptor 1) antagonist is orally active and exerts reversal of carrageenan-induced thermal hyperalgesia models in rats (Fig. 1).¹⁴ Compound **B** is a highly potent and selective hA₃AR (human adenosine A₃ receptor) antagonist with a hA₃AR K_i value reaching 18 nM.¹⁵ Moreover, 7-thia-8-oxoguanosine **C** is a guanosine analogue showing immunostimulatory activity both *in vivo* and *in vitro*,^{16,17} in addition to a broad-spectrum antiviral activity.^{18–20} Also, thiazolidinone **D** was reported to be active against HEPG2 (human liver carcinoma cell line) targeting thymidylate synthase.²¹ Therefore, modifications based on this scaffold

may be a viable strategy for designing new antiproliferative agents. Our previous work has demonstrated that the thiazolo[5,4-*d*]pyrimidine scaffold could be used for designing apoptosis-inducing agents.²² Following our previous work, herein we report the synthesis and the antiproliferative activity against three human cancer cell lines of a series of thiazolo[5,4-*d*]pyrimidine derivatives. We also explored the selectivity of such compounds to MGC-803 cells over GES-1 cells.

The general synthetic route was illustrated in Scheme 1. The intermediate derivatives **5a–b** were synthesized following the previously reported procedure.²³ Then the isothiocyanate analogs reacted with **5a–b** under alkaline conditions (cesium carbonate) in acetonitrile to give the key active intermediates **6a–f**.²⁴ The target compounds **7a–j** were readily obtained by refluxing indicated amines with **6** and triethylamine in isopropanol.

All the target compounds were screened for their antiproliferative activities against human gastric cancer cell lines (MGC-803 and HGC-27) and a human lung cancer cell line (H1650) by the MTT assay (the cells were purchased from the Cell Bank, Shanghai Institutes for Biological Sciences, Shanghai, China), and 5-fluorouracil (5-FU) was employed as the reference drug.²⁵ The antiproliferative results are summarized in Table 1. Generally, most of the synthesized compounds presented moderate to good inhibition toward the tested cancer cell lines, and in particular, were more sensitive to the MGC-803 cell line than the other two cell lines with IC₅₀ values of less than 10 μM. For MGC-803 cells, compounds **7a**, **7c**, and **7i** showed the best inhibitory effect with IC₅₀ values of around 5 μM, comparable to 5-FU. For HGC-27 and H1650 cells, this series of compounds displayed a decreased inhibitory activity with IC₅₀ values of more than 10

Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Key Laboratory of Technology of Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China. E-mail: zzuyubin@hotmail.com, liuhm@zzu.edu.cn

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7md00165g

Fig. 1 Pharmaceutically important thiazolo-pyrimidine derivatives.

Scheme 1 Reagent and conditions: (a) alkyl bromide, TEA, methanol, reflux, 2 h; (b) fuming nitric acid, AcOH, 25–45 °C, 1 h; (c) POCl₃, DMA, reflux, 2 h; (d) Fe, AcOH, methanol, rt ~ reflux; (e) R²SCN, Cs₂CO₃, acetonitrile, rt, overnight; (f) TEA, isopropanol, reflux, 6 h.

μM. Only compound 7i showed a slightly better anti-proliferative activity than 5-FU. For H1650 cells, a similar trend was observed; compounds 7b and 7e were slightly more potent than 5-FU with IC₅₀ values of 8.49 and 5.79 μM, respectively. In general, this series of compounds did not show remarkable structure–activity relationships, highlighting the importance of the thiazolo[5,4-*d*]pyrimidine scaffold in the activity observed. The prioritized one is the compound 7i, which potently inhibited the growth of MGC-803 and HGC27 cells and will be subjected to further mechanistic studies.

The potent inhibition of compounds 7a and 7i against MGC-803 cells prompted us to explore the selectivity between MGC-803 cells and GES-1 cells. As shown in Table 2, these two compounds showed good selectivity with SI values of >12.5 and 12.0, respectively, indicating low toxicity (IC₅₀ > 55 μM against GES-1 cells). The potency and low toxicity of compounds 7a and 7i make the thiazolo[5,4-*d*]pyrimidine an attractive scaffold for designing new derivatives selectively targeting MGC-803 cells.

In light of the acceptable cytotoxicity and low toxicity of compounds 7a and 7i, their molecular properties were calculated online using the free molecular calculation services provided by Molsoft (<http://molsoft.com/mprop>). As shown in Table 3, compounds 7a and 7i exhibited acceptable molecular

properties with a MolLogP value slightly higher than the desirable value.

In conclusion, a series of thiazolo-pyrimidine derivatives were prepared and evaluated for their antiproliferative activity toward several human cancer cell lines. Most of the target compounds showed moderate to good inhibition against the tested cell lines. Among them, compounds 7a and 7i exhibited potent inhibition against MGC-803 cells with IC₅₀ values of 5.13 and 4.64 μM, respectively and showed at least 12-fold selectivity between MGC-803 and GES-1, indicating their low toxicity. These results indicated that the thiazolo[5,4-*d*]pyrimidine scaffold may serve as a template for designing new anticancer agents.

Conflict of interest

The authors declare no competing interests.

Acknowledgements

This work was supported by the National Key Research Programs of Proteins (2016YFA0501800), the National Natural Science Foundation of China (Project No. 81430085 and No.

Table 1 Antiproliferative activities of thiazolo-pyrimidine derivatives against three cancer cell lines

Compound	R ¹	R ²	R ³ N	IC ₅₀ ^a (μM)		
				MGC-803	HGC27	H1650
7a	Propyl	Ph		5.13 ± 0.71	16.17 ± 1.20	13.36 ± 1.12
7b	Propyl	Ph		9.84 ± 0.99	12.26 ± 1.50	8.49 ± 0.92
7c	Propyl	Ph		4.81 ± 0.68	18.90 ± 1.27	21.73 ± 1.65
7d	Propyl	3,4,5-triMeO-Ph		14.50 ± 0.65	27.56 ± 0.87	36.93 ± 3.06
7e	Propyl	2-Cl-Ph		6.07 ± 0.78	10.30 ± 1.01	5.79 ± 0.86
7f	Propyl	2-Cl-Ph		7.78 ± 0.89	10.62 ± 1.02	12.95 ± 2.16
7g	Propyl			8.63 ± 0.96	10.23 ± 0.79	13.13 ± 2.01
7h	Propyl			30.80 ± 1.48	13.50 ± 1.13	18.73 ± 2.66
7i	Bn-	Ph		4.64 ± 0.66	5.07 ± 0.70	13.83 ± 1.14
7j	Bn-	Ph		9.91 ± 0.99	>64	15.73 ± 0.36
5-FU	—	—	—	6.56 ± 0.31	8.22 ± 0.98	12.52 ± 1.53

^a Inhibitory activity was assayed by exposure for 72 h to the substrate and expressed as the concentration required to inhibit tumor cell proliferation by 50% (IC₅₀). Data are presented as the means ± SDs of three independent experiments.

Table 2 Selectivity of compounds 7a and 7i between MGC-803 and GES-1

Compound	IC ₅₀ ^a (μM)		SI ^b
	MGC-803	GES-1	
7a	5.13 ± 0.71	>64	>12.5
7i	4.64 ± 0.66	55.84 ± 0.99	12.0

^a Inhibitory activity was assayed by exposure for 72 h to the substance and expressed as the concentration required to inhibit tumor cell proliferation by 50% (IC₅₀). Data are presented as the means ± SDs of three independent experiments. ^b The selectivity index (SI) was calculated based on the IC₅₀ (GES-1) and IC₅₀ (MGC803) data.

21372206 for H.-M. L.), the Key Research Program of Henan Province (No. 1611003110100 for H.-M. L.), and the Starting Grant of Zhengzhou University (No. 32210533 for B. Yu).

References

- S. Wang, L. J. Zhao and Y. C. Zheng, *et al.* Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors, *Eur. J. Med. Chem.*, 2017, 125, 940–951.
- X. J. Shi, B. Yu and J. W. Wang, *et al.* Structurally novel steroidal spirooxindole by241 potently inhibits tumor growth mainly through ROS-mediated mechanisms, *Sci. Rep.*, 2016, 6, 31607.
- B. Yu, P. P. Qi and X. J. Shi, *et al.* Efficient synthesis of new antiproliferative steroidal hybrids using the molecular hybridization approach, *Eur. J. Med. Chem.*, 2016, 117, 241–255.
- B. Yu, H. Xing and D. Q. Yu, *et al.* Catalytic asymmetric synthesis of biologically important 3-hydroxyoxindoles: an update, *Beilstein J. Org. Chem.*, 2016, 12, 1000–1039.
- R. Lin, S. G. Johnson and P. J. Connolly, *et al.* Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, *Bioorg. Med. Chem. Lett.*, 2009, 19(8), 2333–2337.
- H. T. Fahmy, S. A. Rostom and M. N. Saudi, *et al.* Synthesis and in vitro evaluation of the anticancer activity of novel fluorinated thiazolo[4, 5-d]pyrimidines, *Arch. Pharm.*, 2003, 336(4–5), 216–225.
- Z. Q. Yu, R. Paul and C. Bhattacharya, *et al.* Structural features facilitating tumor cell targeting and internalization by bleomycin and its disaccharide, *Biochemistry*, 2015, 54(19), 3100–3109.

Table 3 Molecular properties of **7a** and **7i**^a

Compound	MW	HBA	HBD	Mol log <i>P</i>	MolPSA (Å ²)	MV (Å ³)
Desirable value	<500	<10	<5	<5	<140	—
7a	486.19	7	1	5.82	62.61	476.71
7i	448.15	6	1	5.47	43.92	411.88

^a MW: molecular weight; HBA: number of hydrogen bond acceptors; HBD: number of hydrogen bond donors; Mol log *P*: log *P* value predicted by Molsoft; MolPSA: topological polar surface area; MV: molecular volume.

- 8 Z. Q. Yu, R. M. Schmaltz and T. C. Bozeman, *et al.* Selective tumor cell targeting by the disaccharide moiety of bleomycin, *J. Am. Chem. Soc.*, 2013, 135(8), 2883–2886.
- 9 S. Baljinder, K. Santosh and P. F. Geng, *et al.* Synthesis, antiproliferative and apoptosis-inducing activity of thiazolo[5,4-d]pyrimidines, *Eur. J. Med. Chem.*, 2013, 70, 864–874.
- 10 M. Y. Jang, S. De Jonghe and K. Segers, *et al.* Synthesis of novel 5-amino-thiazolo[4,5-d]pyrimidines as E. coli and S. aureus SecA inhibitors, *Bioorg. Med. Chem.*, 2011, 19(1), 702–714.
- 11 A. A. Bekhit, H. T. Fahmy and S. A. Rostom, *et al.* Design and synthesis of some substituted 1H-pyrazolyl-thiazolo[4,5-d]pyrimidines as anti-inflammatory-antimicrobial Agents, *Eur. J. Med. Chem.*, 2003, 38(1), 27–36.
- 12 F. Varano, D. Catarzi and F. Vincenzi, *et al.* Design, synthesis, and pharmacological characterization of 2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine derivatives: new highly potent A2A adenosine receptor inverse agonists with antinociceptive activity, *J. Med. Chem.*, 2016, 59(23), 10564–10576.
- 13 A. F. Lewis, J. C. Drach and S. M. Fennewald, *et al.* Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring system, *Antimicrob. Agents Chemother.*, 1994, 38(12), 2889–2895.
- 14 A. D. Lebsack, B. J. Branstetter and M. D. Hack, *et al.* Identification and synthesis of 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives as TRPV1 antagonists, *Bioorg. Med. Chem. Lett.*, 2009, 19(1), 40–46.
- 15 F. Varano, D. Catarzi and L. Squarcialupi, *et al.* Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation, *Eur. J. Med. Chem.*, 2015, 96, 105–121.
- 16 M. Colic, D. Jandric and S. Gasic, *et al.* Immunosine (7-thia-8-oxoguanosine) acts as a cofactor for proliferation of T cells, *Fundam. Clin. Pharmacol.*, 2000, 14(3), 209–217.
- 17 B. S. Sharma, S. Mhaskar and L. Balazs, *et al.* Immunomodulatory activity of a novel nucleoside, 7-thia-8-oxoguanosine: I. Activation of natural killer cells in mice, *Immunopharmacol. Immunotoxicol.*, 1992, 14(1–2), 1–19.
- 18 D. F. Smee, H. A. Alaghamandan and H. B. Cottam, *et al.* Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent, *Antimicrob. Agents Chemother.*, 1989, 33(9), 1487–1492.
- 19 D. F. Smee, H. A. Alaghamandan and H. B. Cottam, *et al.* Antiviral activity of the novel immune modulator 7-thia-8-oxoguanosine, *J. Biol. Response Modif.*, 1990, 9(1), 24–32.
- 20 D. F. Smee, H. A. Alaghamandan and A. Jin, *et al.* Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice, *Antiviral Res.*, 1990, 13(2), 91–102.
- 21 M. I. El-Zahar, S. S. Adb El-Karim and M. E. Haiba, *et al.* Synthesis, antitumor activity and molecular docking study of novel benzofuran-2-yl pyrazole pyrimidine derivatives, *Acta Pol. Pharm.*, 2011, 68(3), 357–373.
- 22 Z. H. Li, J. Zhang and X. Q. Liu, *et al.* Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy, *Eur. J. Med. Chem.*, 2017, 135, 204–212.
- 23 Z. H. Li, D. X. Yang and P. F. Geng, *et al.* Design, synthesis and biological evaluation of [1,2,3]triazolo[4,5-d]pyrimidine derivatives possessing a hydrazone moiety as antiproliferative agents, *Eur. J. Med. Chem.*, 2016, 124, 967–980.
- 24 J. Liu, R. J. Patch and C. Schubert, *et al.* Single-step syntheses of 2-amino-7-chlorothiazolo[5,4-d]pyrimidines: intermediates for bivalent thiazolopyrimidines, *J. Org. Chem.*, 2005, 70(24), 10194–10197.
- 25 Y. C. Duan, Y. C. Ma and E. Zhang, *et al.* Design and synthesis of novel 1,2,3-triazole/dithiocarbamate hybrids as potential anticancer agents, *Eur. J. Med. Chem.*, 2013, 62, 11–19.